NEW
Dupixent

Dupixent

dupilumab

Manufacturer:

sanofi-aventis

Distributor:

DKSH
Concise Prescribing Info
Contents
Dupilumab
Indications/Uses
Moderate to severe atopic dermatitis in patients ≥12 yr who require chronic treatment & whose disease is not adequately controlled or not advisable w/ topical prescription therapies; can be used w/ or w/o topical corticosteroids. Add-on maintenance treatment for severe asthma w/ type 2 inflammation in adults & adolescents ≥12 yr. Maintenance therapy for oral corticosteroid-dependent asthma.
Dosage/Direction for Use
SC Atopic dermatitis Adult Initial dose: 600 mg (two 300 mg inj), followed by 300 mg given every other wk. Adolescent 12-17 yr (≥60 kg) Initial dose: 600 mg (two 300 mg inj) followed by 300 mg given every other wk, (<60 kg) Initial dose: 400 mg (two 200 mg inj) followed by 200 mg given every other wk. Asthma Adult & adolescent ≥12 yr Initial dose: 400 mg (two 200 mg inj) followed by 200 mg given every other wk. Patient w/ oral corticosteroid-dependent asthma or w/ co-morbid moderate-to-severe atopic dermatitis Initial dose: 600 mg (two 300 mg inj) followed by 300 mg given every other wk.
Contraindications
Special Precautions
Institute appropriate therapy & discontinue use if clinically significant hypersensitivity reaction occurs. Conjunctivitis & keratitis; advise patients to report new onset or worsening eye symptoms. Observe for vasculitic rash, worsening pulmonary symptoms, cardiac complications, &/or neuropathy presenting in patients w/ eosinophilia. Not for acute asthma symptoms or exacerbations; acute bronchospasm or status asthmaticus. Do not abruptly discontinue systemic, topical, or inhaled corticosteroids upon initiation of Dupixent. Patients w/ co-morbid asthma. Treat pre-existing helminth infection before initiating therapy. Pregnancy & lactation. Childn <12 yr.
Adverse Reactions
Inj site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other HSV infection, dry eye. Oropharyngeal pain, eosinophilia.
Drug Interactions
ATC Classification
D11AH05 - dupilumab ; Belongs to the class of agents for atopic dermatitis, excluding corticosteroids. Used in the treatment of atopic dermatitis.
Presentation/Packing
Form
Dupixent soln for inj 200 mg/1.14 mL
Packing/Price
2 × 1's
Form
Dupixent soln for inj 300 mg/2 mL
Packing/Price
2 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in